Global Neurological Biomarkers Market Size, Share, Growth & Trends Analysis Report By Type of Biomarker (Proteomic Biomarkers, Genomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers) By Product Type (Reagents and Kits, Assay Kits, Instruments, Software) By Application (Alzheimer’s disease Biomarkers, Parkinson’s disease Biomarkers, Multiple Sclerosis Biomarkers, Other Neurological Disorders) By End-User (Hospitals and Clinics, Diagnostic Laboratories, Dental Clinics): Regional Outlook, Growth Potential and Segments Forecast 2024-2031


Summary of Report:

The Global Neurological Biomarkers Market size was USD 9.02 billion in 2023 and it is expected to grow to USD 18.34 billion in 2031 with a CAGR of 12.78% in the 2024-2031 period. 


Original price was: $3,999.00.Current price is: $2,999.00.
Original price was: $4,999.00.Current price is: $3,999.00.
Original price was: $9,999.00.Current price is: $8,999.00.

Do You have any Budget constraints?
Simply Ask our Sales Team About it.



Global Neurological Biomarkers Market: Overview

The global neurological biomarkers market refers to the economic activity surrounding the development, production, and use of measurable indicators specific to the nervous system. These biomarkers act as signals, providing valuable information about the health and function of the brain and spinal cord. Biomarkers play a crucial role in personalized medicine, allowing for tailored treatment approaches based on individual patient profiles.

New technologies like genomics, proteomics, and imaging are enabling the development of more sophisticated and reliable biomarkers. The increasing prevalence of neurodegenerative diseases like Alzheimer’s and Parkinson’s is fuelling demand for accurate and early diagnosis. Recognizing the potential of biomarkers, both governments and private companies are increasing their investments in research and development. This will further accelerate the development and adoption of new biomarker-based diagnostic tools and therapies.

The specific segments within the market are expected to experience varied growth rates. For instance, the liquid biopsy segment is projected to grow at a faster pace due to its minimally invasive nature and potential for early disease detection.

Global Neurological Biomarkers Market: Covid-19 Impact

As researchers study the long-term neurological sequelae of COVID-19, such as “long COVID”, there is a growing interest in identifying biomarkers for these chronic conditions. This could lead to new developments in the neurological biomarker market. Increased public awareness and concern about the neurological impact of COVID-19 could attract new funding opportunities for research and development in this area.

The pandemic highlighted the potential neurological complications associated with COVID-19, prompting research into biomarkers for early detection and monitoring of these complications. This sparked renewed interest in neurological biomarkers in general. The pandemic led to significant disruptions in clinical trials and research studies for neurological biomarkers. This slowed down the progress of new biomarker discoveries and development of diagnostic tools. Lockdowns and resource allocation towards COVID-19 response limited access to routine healthcare services, including diagnostics and biomarker testing for neurological disorders. This delayed diagnoses and potentially worsened disease outcomes.

Research funding and resources were largely diverted towards COVID-19 research, leading to decreased funding for other areas like neurological biomarker research. Overall, the COVID-19 pandemic has had both negative and positive impacts on the Global Neurological Biomarkers Market. While it caused disruptions and setbacks, it also highlighted the importance of neurological biomarkers and created new opportunities for research and development.

Global Neurological Biomarkers Market: Growth Drivers

1. Technological Advancements in Diagnostic Tools:

Continuous improvements in diagnostic technologies, such as advanced imaging techniques, high-throughput genomics, and sensitive biomarker detection methods, are driving the development of more precise and reliable neurological biomarker assays.

2. Advancements in Biomarker Discovery Technologies: 

Ongoing advancements in genomics, proteomics, and imaging technologies have enabled researchers to identify and validate new biomarkers associated with neurological conditions. These technological advancements enhance the sensitivity and specificity of biomarker assays, driving their adoption in clinical settings.

3. Increasing Incidence of Neurological Disorders:

The rising prevalence of neurological disorders, including Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis, is a significant driver for the neurological biomarkers market. As the global population ages, the incidence of these disorders is expected to increase, creating a growing demand for accurate and early diagnostic tools.

Global Neurological Biomarkers Market: Restraining factors

1. Ethical and Privacy Concerns:

The collection and use of biomarker data, especially genetic information, raise ethical and privacy concerns. Patient consent, data security, and adherence to ethical guidelines are critical considerations that can pose challenges for biomarker research and implementation.

2. Lack of Standardization and Validation:

Standardizing biomarker assays and establishing universally accepted validation protocols can be challenging. The lack of standardized methods for biomarker detection and validation may hinder the reproducibility and comparability of results across different studies and laboratories.

Global Neurological Biomarkers Market:  Opportunity factors

1. Increasing Research in Neuroscience:

The continued growth of research in neuroscience provides opportunities for the identification and validation of new neurological biomarkers. Advancements in understanding the molecular and genetic basis of neurological disorders open doors for innovative biomarker discovery.

2. Integration of Biomarkers into Clinical Trials:

Pharmaceutical companies are increasingly incorporating biomarkers into clinical trial designs for drug development. Biomarkers can serve as indicators of treatment response, aiding in patient stratification and the identification of suitable candidates for clinical trials.

Global Neurological Biomarkers Market: Challenges

1. Understanding the Biological Basis of Neurological Diseases: 

The complex nature of neurological diseases and the incomplete understanding of their biological basis pose challenges in identifying reliable biomarkers. More research is needed to elucidate the underlying mechanisms and pathways associated with various neurological disorders.

2. Stringent Regulatory Approval Processes:

The regulatory approval processes for biomarker-based diagnostics can be lengthy and stringent. Meeting the regulatory requirements for safety and efficacy may pose challenges, delaying the commercialization of new biomarker products.

Global Neurological Biomarkers Market: Segmentation

  • Based On Type of Biomarker: The market is segmented into Proteomic Biomarkers, Genomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers. Among these the Imaging Biomarkers is major revenue contributor.  
  • Based On Type: The market is segmented into Reagents and Kits, Assay Kits, Instruments and Software. Among these Reagents and Kits hold the largest revenue share. 
  • Based On Application: Based on Application segmentation, the market is further divided into Alzheimer’s disease Biomarkers, Parkinson’s disease Biomarkers, Multiple Sclerosis Biomarkers, Other Neurological Disorders. Among these, the Alzheimer’s Disease Biomarkers hold the larger revenue share.
  • Based On End-User: Based on End-User segmentation, the market is further divided into Hospitals and Clinics, Diagnostic Laboratories, and Research Institutes. Among these, the Hospitals & Clinics contributes largest revenue share.
  • Based On Region: Based on Region, the market is segmented into five key geographical regions namely – North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Global Neurological Biomarkers Market: Regional Insights

1. North America

North America currently holds the largest market share due to factors like high healthcare expenditure, extensive research infrastructure, and early adoption of new technologies. Significant research and development efforts are directed towards Alzheimer’s disease biomarkers, driven by a large aging population and high disease burden. The complex regulatory landscape can pose challenges for market entry and commercialization of new biomarkers.

2. Europe

Europe follows North America in market size shows steady growth due to increasing government investments in research and development, rising awareness of neurological diseases, and a large aging population. European countries are at the forefront of personalized medicine initiatives, driving the adoption of biomarker-based diagnostics and treatment strategies. Market dynamics vary across different European countries due to differences in healthcare systems, reimbursement policies, and disease prevalence.

3. Asia-Pacific

Asia Pacific demonstrates expected to witness the highest CAGR due to a rapidly aging population, rising disposable incomes, and increasing investments in healthcare infrastructure. China and India are leading the growth in this region, with significant government initiatives and private investments boosting the market. Limited access to advanced diagnostic technologies and skilled healthcare professionals in some developing countries pose challenges.

4. Latin America & MEA

Latin America experiencing moderate growth due to increasing awareness of neurological diseases and improving healthcare infrastructure. Limited research funding, inadequate healthcare facilities, and high costs of technology pose obstacles to market expansion. These regions present promising opportunities for market growth with increased investments in research, development, and healthcare access.

Competitive Landscape

  • PerkinElmer, Inc,
  • Bio-Rad Laboratories, Inc,
  • MYRIAD RBM, Neurobio,
  • Baxter International,
  • Thermo Fisher Scientific, Inc.,
  • Quanterix, bioMérieux,
  • Merck KGAA.

Global Neurological Biomarkers Market: Recent Developments

  • Bio-Rad Laboratories, Inc: In January 2024, Bio-Rad announced the launch of its QX200 Droplet Digital PCR System, a compact and affordable system for high-throughput and precise gene expression analysis.
  • MYRIAD RBM: In September 2023, Myriad RBM acquired Counsyl, a leader in non-invasive prenatal testing (NIPT), expanding their offerings in women’s health and prenatal care.

Table of Content

2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Modality
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6.1. Overview
6.2. Reagents and Kits
6.3. Assay Kits
6.4. Instruments
6.5. Software
7.1. Overview
7.2. Proteomic Biomarkers
7.3. Genomic Biomarkers
7.4. Metabolomic Biomarkers
7.5. Imaging Biomarkers
8.1. Overview
8.2. Alzheimer’s disease Biomarkers
8.3. Parkinson’s disease Biomarkers
8.4. Multiple Sclerosis Biomarkers
8.5. Other Neurological Disorders
9.1. Overview
9.2. Hospitals and Clinics
9.3. Diagnostic Laboratories
9.4. Research Institutes
10.1. Overview
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. Germany
10.3.2. France
10.3.3. U.K
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. India
10.4.3. Japan
10.4.4. South Korea
10.4.5. Australia
10.4.6. Rest of Asia-Pacific
10.5. Rest of the World
10.5.1. Middle East
10.5.2. Africa
10.5.3. Latin America
11.1. Overview
11.2. Competitive Analysis
11.3. Market Share Analysis
11.4. Major Growth Strategy in the Global Neurological Biomarkers Market,
11.5. Competitive Benchmarking
11.6. Leading Players in Terms of Number of Developments in the Global Neurological Biomarkers Market,
11.7. Key developments and Growth Strategies
11.7.1. New Product/End-Use Deployment
11.7.2. Merger & Acquisitions
11.7.3. Joint Ventures
11.8. Major Players Financial Matrix
11.8.1. Sales & Operating Income, 2022
11.8.2. Major Players R&D Expenditure. 2022
12.1. PerkinElmer, Inc
12.1.1. Company Overview
12.1.2. Financial Overview
12.1.3. Products Offered
12.1.4. Key Developments
12.1.5. SWOT Analysis
12.1.6. Key Strategies
12.2. Bio-Rad Laboratories, Inc
12.2.1. Company Overview
12.2.2. Financial Overview
12.2.3. Products Offered
12.2.4. Key Developments
12.2.5. SWOT Analysis
12.2.6. Key Strategies
12.3.1. Company Overview
12.3.2. Financial Overview
12.3.3. Products Offered
12.3.4. Key Developments
12.3.5. SWOT Analysis
12.3.6. Key Strategies
12.4. Neurobio
12.4.1. Company Overview
12.4.2. Financial Overview
12.4.3. Products Offered
12.4.4. Key Developments
12.4.5. SWOT Analysis
12.4.6. Key Strategies
12.5. Baxter International
12.5.1. Company Overview
12.5.2. Financial Overview
12.5.3. Products Offered
12.5.4. Key Developments
12.5.5. SWOT Analysis
12.5.6. Key Strategies
12.6.1. Company Overview
12.6.2. Financial Overview
12.6.3. Products Offered
12.6.4. Key Developments
12.6.5. SWOT Analysis
12.6.6. Key Strategies
12.7. Thermo Fisher Scientific, Inc.
12.7.1. Company Overview
12.7.2. Financial Overview
12.7.3. Products Offered
12.7.4. Key Developments
12.7.5. SWOT Analysis
12.7.6. Key Strategies
12.8. Quanterix
12.8.1. Company Overview
12.8.2. Financial Overview
12.8.3. Products Offered
12.8.4. Key Developments
12.8.5. SWOT Analysis
12.8.6. Key Strategies
12.9. bioMérieux
12.9.1. Company Overview
12.9.2. Financial Overview
12.9.3. Products Offered
12.9.4. Key Developments
12.9.5. SWOT Analysis
12.9.6. Key Strategies
12.10. Merck KGAA
12.10.1. Company Overview
12.10.2. Financial Overview
12.10.3. Products Offered
12.10.4. Key Developments
12.10.5. SWOT Analysis
12.10.6. Key Strategies

Frequently Asked Questions

  • Which is the leading segment in the Global Neurological Biomarkers Market?

    Among End-Users, Hospitals dominate the market share. This is because Hospitals cater to a wider range of medical specialties and attract a significantly higher volume of patients.
  • What are the key factors driving the Global Neurological Biomarkers Market?

    Increasing Regulatory Support, Technological Advancements in Diagnostic Tools, Growing Emphasis on Early Diagnosis and Disease Monitoring and Increasing Incidence of Neurological Disorders are the major factors driving the market growth.
  • Which region will contribute notably towards the Global Neurological Biomarkers Market?

    North America region to contribute the major share towards the market growth
  • What are the key players in Global Neurological Biomarkers Market?

    PerkinElmer, Inc, Bio-Rad Laboratories, Inc, MYRIAD RBM, Neurobio, Baxter International, F. HOFFMANN-LA ROCHE LTD, Thermo Fisher Scientific, Inc., Quanterix, bioMérieux, Merck KGAA.